We are live on ! Find out more
SLRN

ACELYRIN

Delisted

SLRN was delisted on the 21st of May, 2025.

112 hedge funds and large institutions have $384M invested in ACELYRIN in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 44 increasing their positions, 25 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 25

18% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 22

3% more funds holding

Funds holding: 109112 (+3)

5.5% less ownership

Funds ownership: 93.35%87.84% (-5.5%)

19% less call options, than puts

Call options by funds: $47K | Put options by funds: $58K

37% less capital invested

Capital invested by funds: $613M → $384M (-$230M)

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
112
Holders Change
+3
Holders Change %
+2.75%
% of All Funds
1.62%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
26
Increased
44
Reduced
25
Closed
22
Calls
$47K
Puts
$58K
Net Calls
-$11K
Net Calls Change
+$1.98M
Name Holding Trade Value Shares
Change
Change in
Stake
ACMC
1
AyurMaya Capital Management Company
New Hampshire
$41.2M
Citadel Advisors
2
Citadel Advisors
Florida
$32.7M +$1.79M +381,727 +5%
BlackRock
3
BlackRock
New York
$23.2M +$2.23M +476,644 +10%
Vanguard Group
4
Vanguard Group
Pennsylvania
$20.9M -$7M -1,494,142 -24%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$20.8M -$11.1M -2,365,038 -33%
Millennium Management
6
Millennium Management
New York
$20.5M +$2.95M +628,528 +16%
O
7
OrbiMed
New York
$17.6M
VP
8
venBio Partners
California
$17M
T. Rowe Price Investment Management
9
T. Rowe Price Investment Management
Maryland
$14.8M +$5.78M +1,232,716 +58%
BOCH
10
Blue Owl Capital Holdings
New York
$12.9M +$469K +100,000 +4%
TCM
11
Tybourne Capital Management
Hong Kong
$12.8M
GA
12
General Atlantic
New York
$12.7M
JP Morgan Chase
13
JP Morgan Chase
New York
$11.5M +$30.5K +6,499 +0.3%
SB
14
Samsara BioCapital
California
$11.1M
AG
15
Artal Group
Luxembourg
$8.91M -$1.8M -384,255 -16%
WP
16
Woodline Partners
California
$8.75M +$4.52M +963,606 +94%
PAI
17
Palo Alto Investors
California
$7.56M
OM
18
Opaleye Management
Massachusetts
$6.97M
Jacobs Levy Equity Management
19
Jacobs Levy Equity Management
New Jersey
$6.53M +$4.19M +893,110 +152%
IC
20
Ikarian Capital
Texas
$6.51M -$418K -89,266 -6%
Adage Capital Partners
21
Adage Capital Partners
Massachusetts
$6.17M -$8.81M -1,880,000 -57%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$5.57M +$155K +32,988 +3%
Morgan Stanley
23
Morgan Stanley
New York
$5.52M +$2.75M +587,153 +88%
State Street
24
State Street
Massachusetts
$5.1M +$134K +28,682 +3%
RI
25
RTW Investments
New York
$4.31M

SLRN Hedge Fund Activity: Q2 2024 in Review

112 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q2 2024, worth a combined $384M — down 37% from $613M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new SLRN positions and 22 closed out — a net gain of 4 holders — while 44 added to existing stakes and 25 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $5.78M. The largest seller was Fidelity Investments, cutting an estimated $11.1M.

  • 112 institutional investors held ACELYRIN (SLRN) as of Q2 2024, up from 109 in Q1 2024.
  • Funds reported $384M of ACELYRIN stock for Q2 2024, down 37% quarter-over-quarter.
  • 26 funds opened new ACELYRIN positions in Q2 2024 and 22 closed out, a net change of +4 holders.
  • The largest ACELYRIN buyer in Q2 2024 was T. Rowe Price Investment Management, an estimated $5.78M added.
  • The largest ACELYRIN seller in Q2 2024 was Fidelity Investments, an estimated $11.1M sold.

Based on aggregated 13F filings for Q2 2024.